The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

Beam Therapeutics (BEAM) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical ...

Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.

Netflix's "Black Mirror" is a provocative, imaginative, and often extremely disturbing sci-fi horror TV anthology that ...

Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).

Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation ...

Based on an NFL model of brain trauma, researchers delivered a mild impact to the heads of awake, 9-month-old female rats ...

Beam’s therapy employs base editing to perform ... which will enroll AATD patients with mild-to-moderate liver disease. Other biotech companies are developing potential AATD therapies.